Alternative Choices

17/02/2026

27/01/2026

🧪🌿 Cannabis-derived compounds show promise against drug-resistant fungal infections.

Scientists at Macquarie University have identified CBD and CBDV, two compounds found in cannabis, as powerful antifungal agents. In laboratory studies, these compounds were highly effective against Cryptococcus neoformans—a dangerous fungus that can cause life-threatening meningitis.

Notably, CBD and CBDV acted faster than some existing antifungal medications, damaging fungal cell membranes and disrupting critical metabolic processes. The compounds also showed activity against common fungi responsible for skin conditions such as athlete’s foot and groin fungal infections.

With antifungal drug resistance increasing globally and treatment options becoming more limited, these findings highlight the potential of plant-derived compounds as future therapeutic tools. While further research is needed before clinical use, especially for internal infections, the study supports the development of CBD-based antifungal treatments, particularly for topical applications.

Another example of how the cannabis plant continues to reveal new medical possibilities.

26/01/2026

Stronger bones… from cannabis? 🦴🌿

It might sound surprising, but emerging research suggests CBD (cannabidiol) could play a powerful role in bone health.

A landmark study from Tel Aviv University and the Hebrew University of Jerusalem, published in the Journal of Bone and Mineral Research, found that CBD helped fractures heal faster and made bones stronger than before—without the “high” linked to THC.

🧬 How it works:�CBD interacts with cannabinoid receptors found in our skeleton (yes, bones have them!). It appears to:
* Improve collagen quality during early fracture healing
* Speed up mineralisation of new bone
* Inhibit receptors linked to bone loss, supporting stronger bone density

👥 Who might benefit?�From people with osteoporosis and postmenopausal women, to athletes recovering from injuries, CBD’s anti-inflammatory and bone-supporting properties could be a game changer.

⚠️ While human studies are still limited, CBD is generally well tolerated and recognised by the WHO as having no abuse or dependence potential. As always, quality products and medical guidance matter.

The takeaway: CBD won’t replace good nutrition or exercise—but science is increasingly showing it could be a valuable ally for long-term skeletal health.

09/01/2026

Cannabis-based medicines improved pain, sleep, anxiety and quality of life in 497 fibromyalgia patients over 18 months, according to new data from the UK Medical Cannabis Registry.

"This study found improvements in fibromyalgia-specific outcomes at a long-term follow-up of 18 months, although these gradually declined over time, with peak improvement from baseline seen at 1 month and lowest at 18 months," the study said.

Notably, higher CBD doses were associated with better outcomes compared to lower doses, and current cannabis users saw better results than those who had never used it. However, higher THC doses were not associated with increased odds of improvement in any of the measures.

19/12/2025

A recent Brazilian clinical trial, published in the Journal of Alzheimer’s Disease and widely reported in December 2025, marks a groundbreaking development in exploring cannabis for Alzheimer’s treatment.

Researchers at the Federal University of Latin American Integration conducted a phase 2, randomized, double-blind, placebo-controlled study involving elderly patients aged 60-80 with mild Alzheimer’s disease.

Building on prior animal studies showing low-dose THC restoring cognition in aged mice and a 2022 case report where microdosing improved symptoms in one patient over 22 months, this trial tested daily oral microdoses of a balanced cannabis extract containing approximately 0.3 mg THC and 0.3 mg CBD—far below psychoactive levels.

Over 24-26 weeks, the treatment group showed stabilized cognitive function, as measured by the Mini-Mental State Examination (MMSE), while the placebo group experienced typical decline.

This pausing of progression represents the first human trial evidence of microdosing cannabinoids potentially halting Alzheimer’s-related cognitive deterioration without significant side effects.

Described as unprecedented, the approach leverages the endocannabinoid system’s role in neuroprotection, which naturally diminishes with age. Though promising, the study’s small sample size and limited scope to certain cognitive metrics highlight the need for larger, longer trials to confirm efficacy and safety.

Current Alzheimer’s therapies offer minimal benefit and often severe side effects, making this low-risk cannabinoid option a hopeful avenue amid rising dementia cases globally.

03/12/2025

We now have B12 available..